Citation only
via OpenAlex
Abstract 6826: Age-dependent neuro-immune changes in glioblastoma shape therapeutic response and reveal senescent microglia as a targetable vulnerability
Manon Penco-Campillo, Olaya de Dios, Megan Callender, Kristen L. Lauing, Oluwatomilayo Odum, Taylor Koch, Lijie Zhai, Vikram C. Prabhu, Douglas E. Anderson, Anand V. Germanwala, Jigisha P. Thakkar, Prashant V. Bommi, Pilar Sanchez-Góméz, Frederick S. Varn, Derek A. Wainwright
Cancer Research · 2026
Abstract
Abstract Background: Glioblastoma (GBM) is the most common aggressive primary brain tumor, with a median overall survival (OS) of ≈15-18 months despite standard of care (SOC). Aging is a major negative prognostic factor, with older adults showing worse OS. Senescent cells accumulate with age and contribute to poorer outcomes. Senolytics(definition) clear senescent cells and may improve responses in older hosts. While tumor-intrinsic molecular features appear age-independent, the aging brain microenvironment impact on GBM progression and immunity remains unclear. Objective: To define age-associated senescence(definition) patterns in tumor core and peritumoral (PT) brain in GBM patients and mouse models and assess whether senolytic enhance treatment responses in aged syngeneic and humanized GBM models. Methods: MRI-guided tumor core and PT biopsies from GBM patients (<65 vs. ≥65) underwent transcriptomic and single-cell analyses to assess age-related neuro-immune and senescence changes. Senescence across tumor regions was examined in young (7-9 weeks) and aged (97-104 weeks) C57BL/6 and INK-ATTAC mice with intracranial SB28 tumors (n=5/group). Flow cytometry quantified β-gal+ senescent populations among neurons, astrocytes, oligodendrocytes, microglia, and immune infiltrates from tumor core and extratumoral brain. Mice received brain radiation, anti-PD-1, and IDO enzyme inhibition, alone ± senolytics (dasatinib+quercetin) or AP compound-induced clearance p16INK4A+ senescent cells. A human GBM aging model was developed by depleting CD4+, CD8+, CD19+, and NK1.1+ cells in young and aged C57BL/6 mice, prior to patient-derived GBM43 (PDX) intracranial engraftment, followed by SOC radiotherapy + temozolomide ± senolytics. Results: Transcriptomic profiling showed minimal age-related changes in tumor core but marked alterations in older PT tissues. Aged PT microglia exhibited a senescent phenotype with an upregulation of senescence-associated secretory phenotype (SASP) genes. Senolytics or AP compound significantly reduced extratumoral β-gal+ microglia and synergized with radio-immunotherapy to extend OS in aged mice (p<0.05). In the humanized immunodepleted GBM43 PDX model, young and aged mice developed tumors, with faster mortality in older hosts. Therapeutic responses to SOC ± senolytics are ongoing. Conclusions: The PT brain is a key site of age-dependent immune dysfunction in GBM. Senescent microglia may create an immunosuppressive niche that limits the immunotherapy efficacy in older adults. Senolytics may restore treatment efficacy and improve outcomes in older GBM hosts. We developed a novel immunodepleted GBM PDX model to mechanistically evaluate the role of aging in human tumor progression and therapy resistance. Keywords: glioblastoma, peritumoral brain, aging, immunotherapy, senescence, microglia Citation Format: Manon Penco-Campillo, Olaya de Dios, Megan Callender, Kristen L. Lauing, Oluwatomilayo Odum, Taylor Koch, Lijie Zhai, Vikram C. Prabhu, Douglas E. Anderson, Anand V. Germanwala, Jigisha P. Thakkar, Prashant Bommi, Pilar Sanchez-Gomez, Frederick Varn, Derek Wainwright. Age-dependent neuro-immune changes in glioblastoma shape therapeutic response and reveal senescent microglia as a targetable vulnerability [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6826.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1158/1538-7445.am2026-6826
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Penco-Campillo, M., Dios, O.D., Callender, M., Lauing, K.L., Odum, O., Koch, T., Zhai, L., Prabhu, V.C., Anderson, D.E., Germanwala, A.V., Thakkar, J.P., Bommi, P.V., Sanchez-Góméz, P., Varn, F.S., & Wainwright, D.A. (2026). Abstract 6826: Age-dependent neuro-immune changes in glioblastoma shape therapeutic response and reveal senescent microglia as a targetable vulnerability. <em>Cancer Research</em>. https://doi.org/10.1158/1538-7445.am2026-6826
Vancouver
Penco-Campillo M, Dios OD, Callender M, Lauing KL, Odum O, Koch T, et al. Abstract 6826: Age-dependent neuro-immune changes in glioblastoma shape therapeutic response and reveal senescent microglia as a targetable vulnerability. Cancer Research. 2026. doi:10.1158/1538-7445.am2026-6826.
BibTeX
@article{manon2026Abstra,
title = {Abstract 6826: Age-dependent neuro-immune changes in glioblastoma shape therapeutic response and reveal senescent microglia as a targetable vulnerability},
author = {Manon Penco-Campillo and Olaya de Dios and Megan Callender and Kristen L. Lauing and Oluwatomilayo Odum and Taylor Koch and Lijie Zhai and Vikram C. Prabhu and Douglas E. Anderson and Anand V. Germanwala and Jigisha P. Thakkar and Prashant V. Bommi and Pilar Sanchez-Góméz and Frederick S. Varn and Derek A. Wainwright},
journal = {Cancer Research},
year = {2026},
doi = {10.1158/1538-7445.am2026-6826},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cancer Research 2025
Citation only
Abstract 6434: Senolytics decrease senescent microglia, remodel the vasculature, and improve survival in older adults with glioblastoma during co-treatment with immunotherapy
Neuro-Oncology 2024
Open access · OA
CNSC-47. SENOLYTICS ERADICATE SENESCENT MICROGLIA IN THE BRAIN PARENCHYMA AND IMPROVE SURVIVAL IN OLDER ADULT MICE WITH GLIOBLASTOMA
Genes & Development 2020
Preprint · CC-BY
Senescence and the SASP: many therapeutic avenues
bioRxiv (Cold Spring Harbor Laboratory) 2023
Preprint · CC-BY
Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology
The Journal of Prevention of Alzheimer s Disease 2021
Open access · CC-BY
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial
Aging Cell 2022
Open access · CC-BY